文献速递骨软组织肉瘤与黑色素瘤头颈与中枢神经肿瘤

阿伐替尼在携带KIT外显子17突变的黏膜黑色素瘤与胸腺癌转移患者中的差异活性:意大利同情用药计划的初步经验

Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy.
PubMed 文献 · Eur J Cancer · 2022-07-09

本文报道意大利同情用药计划中4例携带KIT外显子17突变的黏膜黑色素瘤或胸腺癌患者接受阿伐替尼治疗的经验,3/4例有反应、1/4例无反应,呈现差异活性。作者认为伊马替尼对KIT外显子17突变无效、免疫治疗 efficacy 低且缺乏标准二线治疗,支持将阿伐替尼纳入治疗武器库,但需进一步前瞻性证据。

要点

  • 4例KIT外显子17突变患者(2例黏膜黑色素瘤、2例胸腺癌)接受阿伐替尼,3/4例有反应、1/4例无反应。
  • KIT外显子17突变占所有激活性KIT突变的11.7%,是1型激酶抑制剂阿伐替尼的潜在分子靶点。
  • 伊马替尼对KIT外显子17突变无活性,黏膜黑色素瘤和胸腺癌均缺乏标准二线系统治疗。

核心结论

  • 阿伐替尼在KIT外显子17突变的黏膜黑色素瘤和胸腺癌中呈现差异活性,3/4例有反应、1/4例无反应。
  • 作者认为伊马替尼对KIT外显子17突变无活性、免疫治疗总体临床疗效低且两种疾病均缺乏标准可用的有效二线系统治疗,支持将阿伐替尼纳入治疗武器库,但需进一步前瞻性证据。

研究设计与样本

  • 意大利同情用药计划中4例携带KIT外显子17突变的黏膜黑色素瘤或胸腺癌患者的病例系列,其中2例为黏膜黑色素瘤、2例为胸腺癌。

主要发现

  • 4例患者中3例对阿伐替尼有反应、1例无反应。
  • KIT激活性突变在肿瘤中占2.9%,在胃肠道间质瘤中患病率最高。
  • KIT外显子17突变通常改变激酶激活环,相对罕见,占所有激活性KIT突变的11.7%。

临床怎么用

  • 作者认为伊马替尼对KIT外显子17突变无活性、免疫治疗总体临床疗效低且两种疾病缺乏标准可用的有效二线系统治疗,支持将阿伐替尼纳入治疗武器库,但需进一步前瞻性证据。

局限性

  • 原文报告需进一步前瞻性证据。
  • 本系列仅报告意大利同情用药计划中4例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Proto-oncogene KIT is the gene encoding the receptor tyrosine kinase protein KIT. Activating mutations are found in 2.9% of neoplasms, with the highest prevalence in gastrointestinal stromal tumour. Exon 17 mutations typically alter the kinase activation loop and are relatively rare, representing 11.7% of all activating KIT mutations. Recently, KIT exon 17 mutants turned out to be a potential molecular target for the type 1 kinase inhibitor avapritinib (BLU-285). OBJECTIVE: In this framework, we aimed at investigating the potential activity of avapritinib in mucosal melanoma and thymic carcinoma, two disease histologies with dismal prognosis, currently lacking evidence-based second line treatment options and in which KIT exon 17 activating mutations could represent a relevant therapeutic target. RESULTS: In this series, we report the only four cases of patients affected by exon 17 mutant mucosal melanoma and thymic carcinoma that have been treated in Italy with avapritinib within a Compassionate Use Program. Two patients harboured mucosal melanoma and the other two were diagnosed with thymic carcinoma. We describe a differential activity of avapritinib (3/4 patients responded, 1/4 did not respond), along with possible hypotheses to justify such differences and potential implications for precision oncology. CONCLUSIONS: Taken together, the inactivity of imatinib on KIT exon 17 mutations, the general low clinical efficacy of immunotherapy, as well as the consequent formal lack of standard available and active second line systemic treatments in both mucosal melanoma and thymic carcinoma, support the implementation of avapritinib in the therapeutic armamentarium, even though further prospective evidence is warranted.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Corti C, Conforti F, Pala L, et al. Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy. Eur J Cancer. 2022. PMID: 35820244. doi:10.1016/j.ejca.2022.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。